| Literature DB >> 19441846 |
Olaf Kinzel1, Laura Llauger-Bufi, Giovanna Pescatore, Michael Rowley, Carsten Schultz-Fademrecht, Edith Monteagudo, Massimiliano Fonsi, Odalys Gonzalez Paz, Fabrizio Fiore, Christian Steinkühler, Philip Jones.
Abstract
The optimization of a potent, class I selective ketone HDAC inhibitor is shown. It possesses optimized pharmacokinetic properties in preclinical species, has a clean off-target profile, and is negative in a microbial mutagenicity (Ames) test. In a mouse xenograft model it shows efficacy comparable to that of vorinostat at a 10-fold reduced dose.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19441846 DOI: 10.1021/jm9004303
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446